trial · primary record
Rimegepant/BHV3000
Pediatric Migraine
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 2100 |
| Primary completion | 2029-01-09 |
| Primary endpoint | To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to <18 years of age) as measured by pain freedom using the number of patients reporting no pain. |
| Registry ID | NCT04649242 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:47.381Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04649242
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.